During the past decade, Capital Region Retina conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 4 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Capital Region Retina" are "Diabetic Macular Edema" (3 trials), "Macular Degeneration" (2 trials) and "Vitreomacular Adhesion" (1 trials). Many other conditions were trialed in "Capital Region Retina" in a lesser frequency.

Most popular intervention types in "Capital Region Retina" are "Drug" (6 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Faricimab" (3 trials), "Sham Procedure" (3 trials), "Ranibizumab" (2 trials), "Abicipar Pegol" (1 trials) and "Abicipar pegol" (1 trials). Other intervention names were less common.

The vast majority of trials in "Capital Region Retina" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Capital Region Retina". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Capital Region Retina, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Capital Region Retina, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".